Table 2 Immunogenicity of candidate gene-derived peptides in CD8+ T cell priming assays
Protein | Peptide | HLA restrictiona | Number of positive tumors (%) | Immunogenic | Positive population |
|---|---|---|---|---|---|
ANGPTL4 | AQNSRIQQLF | B*15 | 4 (7.3) | Yes | 0.75% |
AQNSRIQQL | B*15 | 3 (5.5) | Yes | 1.19% | |
EGLN3 | FLLSLIDRL | A*02 | 9 (16.4) | Yes | 0.11% |
MPLGHIMRL | B*07, B*08, B*35, B*51, B*53 | 8 (14.5) | Yes | 0.37% | |
EAKKKFRNL | B*08 | 1 (1.8) | Yes | 0.13% | |
YVKERSKAM | B*08 | 1 (1.8) | Yes | 0.10% | |
SLIDRLVLY | B*15 | 3 (5.5) | Yes | 0.48% | |
VQPSYATRY | B*15 | 3 (5.5) | No | – | |
NNMT | SQILKHLL | B*08 | 3 (5.5) | Yes | 0.49% |
AESQILKHLL | B*40, B*44 | 4 (7.3) | Yes | 0.41% | |
P4HA2 | AEKELVQSL | B*40, B*41, B*44 | 5 (9.1) | No | – |
PFKP | RSFAGNLNTY | B*15 | 4 (7.3) | No | – |